Platelet aggregation in human whole blood after chronic administration of aspirin.
We have used the impedance aggregometer to study the "ex vivo" effect of acetylsalicylic acid (ASA) in whole blood (WB) versus platelet-rich plasma (PRP) in 35 male healthy volunteers after 10 days of treatment with 25, 50, 125, 250, and 500 mg/day of ASA. Percent of inhibition of platelet aggregation was determinated at the end of treatment. A greater inhibition of platelet aggregation was observed in WB than in PRP when ASA was administrated at almost all doses. Maximal differences were at 25, 50, and 125 mg/day of ASA on adrenaline, collagen and arachidonic acid induced aggregation, and with 250 and 500 mg/day of ASA when ADP was used as aggregating agent. In the "in vitro" trials, IC-50 values of ASA on ADP and collagen induced aggregation were determined in platelet aggregation by the impedance method in both WB and PRP. ASA shows a lower IC-50 in WB than in PRP. When leucocytes were incubated in PRP samples, it effect was similar to the percent of inhibition in WB.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D001773:Blood Cells / Q000502:physiology; D002469:Cell Separation; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D012107:Research Design
D001095:Arachidonic Acids; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D003094:Collagen; D001241:Aspirin; D004837:Epinephrine